Theoretical reduction in the anticholinergic burden in older adults with dementia in New Zealand

Research output: Contribution to conferenceAbstractpeer-review

Abstract

Abstract:
A high prevalence of prescribing potentially inappropriate medications, particularly medications with anticholinergic properties (MAP), has been observed in older adults (>65 years of age) with dementia in New Zealand. MAP have been associated with several adverse outcomes in this vulnerable population, specifically the risk of accelerating cognitive decline in patients with pre-existing dementia.
The purpose of this study was to compile a comprehensive list of therapeutic alternatives to MAP prescribed for comorbidities in individuals with dementia. Further, the list was used in a cohort of patients with dementia, to determine theoretically if a reduction in the anticholinergic burden (ACB) could be achieved.
Original languageEnglish
Publication statusPublished - 25 Jun 2021
Event255th Otago Medical School Research Society Meeting - PhD Student Speaker Awards - New Zealand, Dunedin, New Zealand
Duration: 25 Jun 202125 Jun 2021

Conference

Conference255th Otago Medical School Research Society Meeting - PhD Student Speaker Awards
Country/TerritoryNew Zealand
CityDunedin
Period25/06/2125/06/21

Fingerprint

Dive into the research topics of 'Theoretical reduction in the anticholinergic burden in older adults with dementia in New Zealand'. Together they form a unique fingerprint.

Cite this